Author:
Blondet Laure,Sarabi Matthieu
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Reference6 articles.
1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010
2. Mutations de l’ADN dans les cholangiocarcinomes : cibler IDH1 et autres mutations;Valéry;Bull Cancer,2022
3. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC);Ioka;Proc Am Soc Clin Oncol,2019
4. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study;Oh;Lancet Gastroenterol Hepatol,2022
5. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1;Oh;N Engl J Med Evid,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献